Moderna, Inc. (MRNA) Stock Competitors & Peer Comparison
See (MRNA) competitors and their performances in Stock Market.
Peer Comparison Table: Biotechnology Industry
Detailed financial metrics including price, market cap, P/E ratio, and more.
| Symbol | Price | Change % | Market Cap | P/E Ratio | EPS | Dividend Yield |
|---|---|---|---|---|---|---|
| MRNA | $59.75 | -3.32% | 25.4B | -7.86 | -$8.14 | N/A |
| VRTX | $463.28 | +0.93% | 114.6B | 26.79 | $16.86 | N/A |
| VRNA | $106.91 | +0.11% | 72.7B | -102.80 | -$1.04 | N/A |
| REGN | $608.95 | +0.17% | 62.8B | 14.90 | $40.94 | +0.60% |
| ARGX | $907.59 | +1.72% | 54.3B | 39.03 | $22.49 | N/A |
| SGEN | $228.74 | -0.07% | 43.2B | -57.19 | -$4.00 | N/A |
| ALNY | $283.57 | +0.30% | 37.1B | 70.05 | $3.97 | N/A |
| RVMDW | $7.14 | +11.56% | 35.4B | N/A | N/A | N/A |
| RVMD | $165.69 | +5.02% | 34.7B | -22.92 | -$7.11 | N/A |
| BNTX | $91.64 | -0.63% | 23B | -15.46 | -$5.88 | N/A |
Stock Comparison
MRNA vs VRTX Comparison June 2026
MRNA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, MRNA stands at 25.4B. In comparison, VRTX has a market cap of 114.6B. Regarding current trading prices, MRNA is priced at $59.75, while VRTX trades at $463.28.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
MRNA currently has a P/E ratio of -7.86, whereas VRTX's P/E ratio is 26.79. In terms of profitability, MRNA's ROE is -0.37%, compared to VRTX's ROE of +0.24%. Regarding short-term risk, MRNA is more volatile compared to VRTX. This indicates potentially higher risk in terms of short-term price fluctuations for MRNA.Check VRTX's competition here
MRNA vs VRNA Comparison June 2026
MRNA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, MRNA stands at 25.4B. In comparison, VRNA has a market cap of 72.7B. Regarding current trading prices, MRNA is priced at $59.75, while VRNA trades at $106.91.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
MRNA currently has a P/E ratio of -7.86, whereas VRNA's P/E ratio is -102.80. In terms of profitability, MRNA's ROE is -0.37%, compared to VRNA's ROE of -0.13%. Regarding short-term risk, MRNA is more volatile compared to VRNA. This indicates potentially higher risk in terms of short-term price fluctuations for MRNA.Check VRNA's competition here
MRNA vs REGN Comparison June 2026
MRNA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, MRNA stands at 25.4B. In comparison, REGN has a market cap of 62.8B. Regarding current trading prices, MRNA is priced at $59.75, while REGN trades at $608.95.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
MRNA currently has a P/E ratio of -7.86, whereas REGN's P/E ratio is 14.90. In terms of profitability, MRNA's ROE is -0.37%, compared to REGN's ROE of +0.14%. Regarding short-term risk, MRNA is more volatile compared to REGN. This indicates potentially higher risk in terms of short-term price fluctuations for MRNA.Check REGN's competition here
MRNA vs ARGX Comparison June 2026
MRNA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, MRNA stands at 25.4B. In comparison, ARGX has a market cap of 54.3B. Regarding current trading prices, MRNA is priced at $59.75, while ARGX trades at $907.59.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
MRNA currently has a P/E ratio of -7.86, whereas ARGX's P/E ratio is 39.03. In terms of profitability, MRNA's ROE is -0.37%, compared to ARGX's ROE of +0.37%. Regarding short-term risk, MRNA is more volatile compared to ARGX. This indicates potentially higher risk in terms of short-term price fluctuations for MRNA.Check ARGX's competition here
MRNA vs SGEN Comparison June 2026
MRNA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, MRNA stands at 25.4B. In comparison, SGEN has a market cap of 43.2B. Regarding current trading prices, MRNA is priced at $59.75, while SGEN trades at $228.74.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
MRNA currently has a P/E ratio of -7.86, whereas SGEN's P/E ratio is -57.19. In terms of profitability, MRNA's ROE is -0.37%, compared to SGEN's ROE of -0.21%. Regarding short-term risk, MRNA is more volatile compared to SGEN. This indicates potentially higher risk in terms of short-term price fluctuations for MRNA.Check SGEN's competition here
MRNA vs ALNY Comparison June 2026
MRNA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, MRNA stands at 25.4B. In comparison, ALNY has a market cap of 37.1B. Regarding current trading prices, MRNA is priced at $59.75, while ALNY trades at $283.57.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
MRNA currently has a P/E ratio of -7.86, whereas ALNY's P/E ratio is 70.05. In terms of profitability, MRNA's ROE is -0.37%, compared to ALNY's ROE of +0.98%. Regarding short-term risk, MRNA is more volatile compared to ALNY. This indicates potentially higher risk in terms of short-term price fluctuations for MRNA.Check ALNY's competition here
MRNA vs RVMDW Comparison June 2026
MRNA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, MRNA stands at 25.4B. In comparison, RVMDW has a market cap of 35.4B. Regarding current trading prices, MRNA is priced at $59.75, while RVMDW trades at $7.14.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
MRNA currently has a P/E ratio of -7.86, whereas RVMDW's P/E ratio is N/A. In terms of profitability, MRNA's ROE is -0.37%, compared to RVMDW's ROE of -0.83%. Regarding short-term risk, MRNA is more volatile compared to RVMDW. This indicates potentially higher risk in terms of short-term price fluctuations for MRNA.Check RVMDW's competition here
MRNA vs RVMD Comparison June 2026
MRNA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, MRNA stands at 25.4B. In comparison, RVMD has a market cap of 34.7B. Regarding current trading prices, MRNA is priced at $59.75, while RVMD trades at $165.69.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
MRNA currently has a P/E ratio of -7.86, whereas RVMD's P/E ratio is -22.92. In terms of profitability, MRNA's ROE is -0.37%, compared to RVMD's ROE of -0.83%. Regarding short-term risk, MRNA is more volatile compared to RVMD. This indicates potentially higher risk in terms of short-term price fluctuations for MRNA.Check RVMD's competition here
MRNA vs BNTX Comparison June 2026
MRNA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, MRNA stands at 25.4B. In comparison, BNTX has a market cap of 23B. Regarding current trading prices, MRNA is priced at $59.75, while BNTX trades at $91.64.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
MRNA currently has a P/E ratio of -7.86, whereas BNTX's P/E ratio is -15.46. In terms of profitability, MRNA's ROE is -0.37%, compared to BNTX's ROE of -0.07%. Regarding short-term risk, MRNA is more volatile compared to BNTX. This indicates potentially higher risk in terms of short-term price fluctuations for MRNA.Check BNTX's competition here
MRNA vs RPRX Comparison June 2026
MRNA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, MRNA stands at 25.4B. In comparison, RPRX has a market cap of 22.8B. Regarding current trading prices, MRNA is priced at $59.75, while RPRX trades at $53.48.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
MRNA currently has a P/E ratio of -7.86, whereas RPRX's P/E ratio is 27.87. In terms of profitability, MRNA's ROE is -0.37%, compared to RPRX's ROE of +0.13%. Regarding short-term risk, MRNA is more volatile compared to RPRX. This indicates potentially higher risk in terms of short-term price fluctuations for MRNA.Check RPRX's competition here
MRNA vs UTHR Comparison June 2026
MRNA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, MRNA stands at 25.4B. In comparison, UTHR has a market cap of 22.8B. Regarding current trading prices, MRNA is priced at $59.75, while UTHR trades at $539.05.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
MRNA currently has a P/E ratio of -7.86, whereas UTHR's P/E ratio is 19.85. In terms of profitability, MRNA's ROE is -0.37%, compared to UTHR's ROE of +0.19%. Regarding short-term risk, MRNA is more volatile compared to UTHR. This indicates potentially higher risk in terms of short-term price fluctuations for MRNA.Check UTHR's competition here
MRNA vs ROIV Comparison June 2026
MRNA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, MRNA stands at 25.4B. In comparison, ROIV has a market cap of 22.6B. Regarding current trading prices, MRNA is priced at $59.75, while ROIV trades at $31.53.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
MRNA currently has a P/E ratio of -7.86, whereas ROIV's P/E ratio is -58.20. In terms of profitability, MRNA's ROE is -0.37%, compared to ROIV's ROE of -0.07%. Regarding short-term risk, MRNA is more volatile compared to ROIV. This indicates potentially higher risk in terms of short-term price fluctuations for MRNA.Check ROIV's competition here
MRNA vs INSM Comparison June 2026
MRNA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, MRNA stands at 25.4B. In comparison, INSM has a market cap of 20.8B. Regarding current trading prices, MRNA is priced at $59.75, while INSM trades at $98.21.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
MRNA currently has a P/E ratio of -7.86, whereas INSM's P/E ratio is -16.63. In terms of profitability, MRNA's ROE is -0.37%, compared to INSM's ROE of -1.30%. Regarding short-term risk, MRNA is more volatile compared to INSM. This indicates potentially higher risk in terms of short-term price fluctuations for MRNA.Check INSM's competition here
MRNA vs BGNE Comparison June 2026
MRNA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, MRNA stands at 25.4B. In comparison, BGNE has a market cap of 20.2B. Regarding current trading prices, MRNA is priced at $59.75, while BGNE trades at $184.71.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
MRNA currently has a P/E ratio of -7.86, whereas BGNE's P/E ratio is -22.55. In terms of profitability, MRNA's ROE is -0.37%, compared to BGNE's ROE of +0.12%. Regarding short-term risk, MRNA is more volatile compared to BGNE. This indicates potentially higher risk in terms of short-term price fluctuations for MRNA.Check BGNE's competition here
MRNA vs INCY Comparison June 2026
MRNA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, MRNA stands at 25.4B. In comparison, INCY has a market cap of 19.6B. Regarding current trading prices, MRNA is priced at $59.75, while INCY trades at $102.34.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
MRNA currently has a P/E ratio of -7.86, whereas INCY's P/E ratio is 13.87. In terms of profitability, MRNA's ROE is -0.37%, compared to INCY's ROE of +0.29%. Regarding short-term risk, MRNA is more volatile compared to INCY. This indicates potentially higher risk in terms of short-term price fluctuations for MRNA.Check INCY's competition here
MRNA vs DNA-WT Comparison June 2026
MRNA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, MRNA stands at 25.4B. In comparison, DNA-WT has a market cap of 18.7B. Regarding current trading prices, MRNA is priced at $59.75, while DNA-WT trades at $0.27.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
MRNA currently has a P/E ratio of -7.86, whereas DNA-WT's P/E ratio is N/A. In terms of profitability, MRNA's ROE is -0.37%, compared to DNA-WT's ROE of -0.57%. Regarding short-term risk, MRNA is more volatile compared to DNA-WT. This indicates potentially higher risk in terms of short-term price fluctuations for MRNA.Check DNA-WT's competition here
MRNA vs NBIX Comparison June 2026
MRNA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, MRNA stands at 25.4B. In comparison, NBIX has a market cap of 15.9B. Regarding current trading prices, MRNA is priced at $59.75, while NBIX trades at $159.66.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
MRNA currently has a P/E ratio of -7.86, whereas NBIX's P/E ratio is 24.31. In terms of profitability, MRNA's ROE is -0.37%, compared to NBIX's ROE of +0.22%. Regarding short-term risk, MRNA is more volatile compared to NBIX. This indicates potentially higher risk in terms of short-term price fluctuations for MRNA.Check NBIX's competition here
MRNA vs GMAB Comparison June 2026
MRNA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, MRNA stands at 25.4B. In comparison, GMAB has a market cap of 15.5B. Regarding current trading prices, MRNA is priced at $59.75, while GMAB trades at $25.56.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
MRNA currently has a P/E ratio of -7.86, whereas GMAB's P/E ratio is 19.29. In terms of profitability, MRNA's ROE is -0.37%, compared to GMAB's ROE of +0.15%. Regarding short-term risk, MRNA is more volatile compared to GMAB. This indicates potentially higher risk in terms of short-term price fluctuations for MRNA.Check GMAB's competition here
MRNA vs ASND Comparison June 2026
MRNA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, MRNA stands at 25.4B. In comparison, ASND has a market cap of 14.3B. Regarding current trading prices, MRNA is priced at $59.75, while ASND trades at $231.02.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
MRNA currently has a P/E ratio of -7.86, whereas ASND's P/E ratio is 26.29. In terms of profitability, MRNA's ROE is -0.37%, compared to ASND's ROE of -56.42%. Regarding short-term risk, MRNA is more volatile compared to ASND. This indicates potentially higher risk in terms of short-term price fluctuations for MRNA.Check ASND's competition here
MRNA vs JAZZ Comparison June 2026
MRNA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, MRNA stands at 25.4B. In comparison, JAZZ has a market cap of 14.1B. Regarding current trading prices, MRNA is priced at $59.75, while JAZZ trades at $227.03.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
MRNA currently has a P/E ratio of -7.86, whereas JAZZ's P/E ratio is 2042.36. In terms of profitability, MRNA's ROE is -0.37%, compared to JAZZ's ROE of +0.01%. Regarding short-term risk, MRNA is more volatile compared to JAZZ. This indicates potentially higher risk in terms of short-term price fluctuations for MRNA.Check JAZZ's competition here
MRNA vs EXEL Comparison June 2026
MRNA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, MRNA stands at 25.4B. In comparison, EXEL has a market cap of 13B. Regarding current trading prices, MRNA is priced at $59.75, while EXEL trades at $51.37.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
MRNA currently has a P/E ratio of -7.86, whereas EXEL's P/E ratio is 17.19. In terms of profitability, MRNA's ROE is -0.37%, compared to EXEL's ROE of +0.40%. Regarding short-term risk, MRNA is more volatile compared to EXEL. This indicates potentially higher risk in terms of short-term price fluctuations for MRNA.Check EXEL's competition here
MRNA vs BBIO Comparison June 2026
MRNA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, MRNA stands at 25.4B. In comparison, BBIO has a market cap of 13B. Regarding current trading prices, MRNA is priced at $59.75, while BBIO trades at $69.17.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
MRNA currently has a P/E ratio of -7.86, whereas BBIO's P/E ratio is -17.72. In terms of profitability, MRNA's ROE is -0.37%, compared to BBIO's ROE of +0.36%. Regarding short-term risk, MRNA is more volatile compared to BBIO. This indicates potentially higher risk in terms of short-term price fluctuations for MRNA.Check BBIO's competition here
MRNA vs AXSM Comparison June 2026
MRNA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, MRNA stands at 25.4B. In comparison, AXSM has a market cap of 12.9B. Regarding current trading prices, MRNA is priced at $59.75, while AXSM trades at $248.04.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
MRNA currently has a P/E ratio of -7.86, whereas AXSM's P/E ratio is -67.16. In terms of profitability, MRNA's ROE is -0.37%, compared to AXSM's ROE of -2.60%. Regarding short-term risk, MRNA is more volatile compared to AXSM. This indicates potentially higher risk in terms of short-term price fluctuations for MRNA.Check AXSM's competition here
MRNA vs KRTX Comparison June 2026
MRNA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, MRNA stands at 25.4B. In comparison, KRTX has a market cap of 12.6B. Regarding current trading prices, MRNA is priced at $59.75, while KRTX trades at $329.83.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
MRNA currently has a P/E ratio of -7.86, whereas KRTX's P/E ratio is -28.09. In terms of profitability, MRNA's ROE is -0.37%, compared to KRTX's ROE of -0.36%. Regarding short-term risk, MRNA is more volatile compared to KRTX. This indicates potentially higher risk in terms of short-term price fluctuations for MRNA.Check KRTX's competition here
MRNA vs IONS Comparison June 2026
MRNA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, MRNA stands at 25.4B. In comparison, IONS has a market cap of 12.2B. Regarding current trading prices, MRNA is priced at $59.75, while IONS trades at $76.21.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
MRNA currently has a P/E ratio of -7.86, whereas IONS's P/E ratio is -36.88. In terms of profitability, MRNA's ROE is -0.37%, compared to IONS's ROE of -0.59%. Regarding short-term risk, MRNA is more volatile compared to IONS. This indicates potentially higher risk in terms of short-term price fluctuations for MRNA.Check IONS's competition here
MRNA vs MDGL Comparison June 2026
MRNA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, MRNA stands at 25.4B. In comparison, MDGL has a market cap of 11.7B. Regarding current trading prices, MRNA is priced at $59.75, while MDGL trades at $511.50.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
MRNA currently has a P/E ratio of -7.86, whereas MDGL's P/E ratio is -37.52. In terms of profitability, MRNA's ROE is -0.37%, compared to MDGL's ROE of -0.50%. Regarding short-term risk, MRNA is more volatile compared to MDGL. This indicates potentially higher risk in terms of short-term price fluctuations for MRNA.Check MDGL's competition here
MRNA vs ARWR Comparison June 2026
MRNA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, MRNA stands at 25.4B. In comparison, ARWR has a market cap of 11.5B. Regarding current trading prices, MRNA is priced at $59.75, while ARWR trades at $82.67.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
MRNA currently has a P/E ratio of -7.86, whereas ARWR's P/E ratio is -36.04. In terms of profitability, MRNA's ROE is -0.37%, compared to ARWR's ROE of -0.55%. Regarding short-term risk, MRNA is more volatile compared to ARWR. This indicates potentially higher risk in terms of short-term price fluctuations for MRNA.Check ARWR's competition here
MRNA vs RNAM Comparison June 2026
MRNA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, MRNA stands at 25.4B. In comparison, RNAM has a market cap of 11.3B. Regarding current trading prices, MRNA is priced at $59.75, while RNAM trades at $72.86.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
MRNA currently has a P/E ratio of -7.86, whereas RNAM's P/E ratio is -17.39. In terms of profitability, MRNA's ROE is -0.37%, compared to RNAM's ROE of -0.45%. Regarding short-term risk, MRNA is more volatile compared to RNAM. This indicates potentially higher risk in terms of short-term price fluctuations for MRNA.Check RNAM's competition here
MRNA vs SMMT Comparison June 2026
MRNA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, MRNA stands at 25.4B. In comparison, SMMT has a market cap of 10.7B. Regarding current trading prices, MRNA is priced at $59.75, while SMMT trades at $14.24.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
MRNA currently has a P/E ratio of -7.86, whereas SMMT's P/E ratio is -8.65. In terms of profitability, MRNA's ROE is -0.37%, compared to SMMT's ROE of -3.41%. Regarding short-term risk, MRNA is more volatile compared to SMMT. This indicates potentially higher risk in terms of short-term price fluctuations for MRNA.Check SMMT's competition here
MRNA vs BMRN Comparison June 2026
MRNA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, MRNA stands at 25.4B. In comparison, BMRN has a market cap of 10.6B. Regarding current trading prices, MRNA is priced at $59.75, while BMRN trades at $55.51.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
MRNA currently has a P/E ratio of -7.86, whereas BMRN's P/E ratio is 39.35. In terms of profitability, MRNA's ROE is -0.37%, compared to BMRN's ROE of +0.04%. Regarding short-term risk, MRNA is more volatile compared to BMRN. This indicates potentially higher risk in terms of short-term price fluctuations for MRNA.Check BMRN's competition here
MRNA vs KRYS Comparison June 2026
MRNA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, MRNA stands at 25.4B. In comparison, KRYS has a market cap of 10.3B. Regarding current trading prices, MRNA is priced at $59.75, while KRYS trades at $343.91.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
MRNA currently has a P/E ratio of -7.86, whereas KRYS's P/E ratio is 46.53. In terms of profitability, MRNA's ROE is -0.37%, compared to KRYS's ROE of +0.19%. Regarding short-term risk, MRNA is more volatile compared to KRYS. This indicates potentially higher risk in terms of short-term price fluctuations for MRNA.Check KRYS's competition here
MRNA vs CYTK Comparison June 2026
MRNA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, MRNA stands at 25.4B. In comparison, CYTK has a market cap of 9.8B. Regarding current trading prices, MRNA is priced at $59.75, while CYTK trades at $79.93.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
MRNA currently has a P/E ratio of -7.86, whereas CYTK's P/E ratio is -11.50. In terms of profitability, MRNA's ROE is -0.37%, compared to CYTK's ROE of +1.40%. Regarding short-term risk, MRNA is more volatile compared to CYTK. This indicates potentially higher risk in terms of short-term price fluctuations for MRNA.Check CYTK's competition here
MRNA vs RXDX Comparison June 2026
MRNA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, MRNA stands at 25.4B. In comparison, RXDX has a market cap of 9.6B. Regarding current trading prices, MRNA is priced at $59.75, while RXDX trades at $199.92.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
MRNA currently has a P/E ratio of -7.86, whereas RXDX's P/E ratio is -56.47. In terms of profitability, MRNA's ROE is -0.37%, compared to RXDX's ROE of -0.31%. Regarding short-term risk, MRNA is more volatile compared to RXDX. This indicates potentially higher risk in terms of short-term price fluctuations for MRNA.Check RXDX's competition here
MRNA vs NUVL Comparison June 2026
MRNA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, MRNA stands at 25.4B. In comparison, NUVL has a market cap of 9.1B. Regarding current trading prices, MRNA is priced at $59.75, while NUVL trades at $123.41.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
MRNA currently has a P/E ratio of -7.86, whereas NUVL's P/E ratio is -20.37. In terms of profitability, MRNA's ROE is -0.37%, compared to NUVL's ROE of -0.43%. Regarding short-term risk, MRNA is more volatile compared to NUVL. This indicates potentially higher risk in terms of short-term price fluctuations for MRNA.Check NUVL's competition here
MRNA vs TECH Comparison June 2026
MRNA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, MRNA stands at 25.4B. In comparison, TECH has a market cap of 9.1B. Regarding current trading prices, MRNA is priced at $59.75, while TECH trades at $56.33.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
MRNA currently has a P/E ratio of -7.86, whereas TECH's P/E ratio is 82.77. In terms of profitability, MRNA's ROE is -0.37%, compared to TECH's ROE of +0.05%. Regarding short-term risk, MRNA is more volatile compared to TECH. This indicates potentially higher risk in terms of short-term price fluctuations for MRNA.Check TECH's competition here
MRNA vs IMGN Comparison June 2026
MRNA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, MRNA stands at 25.4B. In comparison, IMGN has a market cap of 8.7B. Regarding current trading prices, MRNA is priced at $59.75, while IMGN trades at $31.24.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
MRNA currently has a P/E ratio of -7.86, whereas IMGN's P/E ratio is -111.55. In terms of profitability, MRNA's ROE is -0.37%, compared to IMGN's ROE of -0.93%. Regarding short-term risk, MRNA is more volatile compared to IMGN. This indicates potentially higher risk in terms of short-term price fluctuations for MRNA.Check IMGN's competition here
MRNA vs CORT Comparison June 2026
MRNA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, MRNA stands at 25.4B. In comparison, CORT has a market cap of 8.6B. Regarding current trading prices, MRNA is priced at $59.75, while CORT trades at $78.66.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
MRNA currently has a P/E ratio of -7.86, whereas CORT's P/E ratio is 228.31. In terms of profitability, MRNA's ROE is -0.37%, compared to CORT's ROE of +0.08%. Regarding short-term risk, MRNA is more volatile compared to CORT. This indicates potentially higher risk in terms of short-term price fluctuations for MRNA.Check CORT's competition here
MRNA vs BPMC Comparison June 2026
MRNA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, MRNA stands at 25.4B. In comparison, BPMC has a market cap of 8.4B. Regarding current trading prices, MRNA is priced at $59.75, while BPMC trades at $129.46.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
MRNA currently has a P/E ratio of -7.86, whereas BPMC's P/E ratio is -51.58. In terms of profitability, MRNA's ROE is -0.37%, compared to BPMC's ROE of -0.15%. Regarding short-term risk, MRNA is more volatile compared to BPMC. This indicates potentially higher risk in terms of short-term price fluctuations for MRNA.Check BPMC's competition here
MRNA vs CERE Comparison June 2026
MRNA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, MRNA stands at 25.4B. In comparison, CERE has a market cap of 8.2B. Regarding current trading prices, MRNA is priced at $59.75, while CERE trades at $44.96.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
MRNA currently has a P/E ratio of -7.86, whereas CERE's P/E ratio is -16.47. In terms of profitability, MRNA's ROE is -0.37%, compared to CERE's ROE of -0.72%. Regarding short-term risk, MRNA is more volatile compared to CERE. This indicates potentially higher risk in terms of short-term price fluctuations for MRNA.Check CERE's competition here
MRNA vs TGTX Comparison June 2026
MRNA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, MRNA stands at 25.4B. In comparison, TGTX has a market cap of 8.1B. Regarding current trading prices, MRNA is priced at $59.75, while TGTX trades at $54.42.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
MRNA currently has a P/E ratio of -7.86, whereas TGTX's P/E ratio is 18.61. In terms of profitability, MRNA's ROE is -0.37%, compared to TGTX's ROE of +0.87%. Regarding short-term risk, MRNA is more volatile compared to TGTX. This indicates potentially higher risk in terms of short-term price fluctuations for MRNA.Check TGTX's competition here
MRNA vs HALO Comparison June 2026
MRNA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, MRNA stands at 25.4B. In comparison, HALO has a market cap of 8.1B. Regarding current trading prices, MRNA is priced at $59.75, while HALO trades at $69.11.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
MRNA currently has a P/E ratio of -7.86, whereas HALO's P/E ratio is 24.05. In terms of profitability, MRNA's ROE is -0.37%, compared to HALO's ROE of +1.26%. Regarding short-term risk, MRNA is more volatile compared to HALO. This indicates potentially higher risk in terms of short-term price fluctuations for MRNA.Check HALO's competition here
MRNA vs IBRX Comparison June 2026
MRNA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, MRNA stands at 25.4B. In comparison, IBRX has a market cap of 7.7B. Regarding current trading prices, MRNA is priced at $59.75, while IBRX trades at $7.21.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
MRNA currently has a P/E ratio of -7.86, whereas IBRX's P/E ratio is -8.66. In terms of profitability, MRNA's ROE is -0.37%, compared to IBRX's ROE of +1.39%. Regarding short-term risk, MRNA is more volatile compared to IBRX. This indicates potentially higher risk in terms of short-term price fluctuations for MRNA.Check IBRX's competition here
MRNA vs ALKS Comparison June 2026
MRNA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, MRNA stands at 25.4B. In comparison, ALKS has a market cap of 7.5B. Regarding current trading prices, MRNA is priced at $59.75, while ALKS trades at $46.04.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
MRNA currently has a P/E ratio of -7.86, whereas ALKS's P/E ratio is 49.99. In terms of profitability, MRNA's ROE is -0.37%, compared to ALKS's ROE of +0.09%. Regarding short-term risk, MRNA is more volatile compared to ALKS. This indicates potentially higher risk in terms of short-term price fluctuations for MRNA.Check ALKS's competition here
MRNA vs KYMR Comparison June 2026
MRNA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, MRNA stands at 25.4B. In comparison, KYMR has a market cap of 7.4B. Regarding current trading prices, MRNA is priced at $59.75, while KYMR trades at $98.92.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
MRNA currently has a P/E ratio of -7.86, whereas KYMR's P/E ratio is -25.26. In terms of profitability, MRNA's ROE is -0.37%, compared to KYMR's ROE of -0.25%. Regarding short-term risk, MRNA is less volatile compared to KYMR. This indicates potentially lower risk in terms of short-term price fluctuations for MRNA.Check KYMR's competition here
MRNA vs MTSR Comparison June 2026
MRNA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, MRNA stands at 25.4B. In comparison, MTSR has a market cap of 7.4B. Regarding current trading prices, MRNA is priced at $59.75, while MTSR trades at $70.50.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
MRNA currently has a P/E ratio of -7.86, whereas MTSR's P/E ratio is -23.58. In terms of profitability, MRNA's ROE is -0.37%, compared to MTSR's ROE of -0.80%. Regarding short-term risk, MRNA is more volatile compared to MTSR. This indicates potentially higher risk in terms of short-term price fluctuations for MRNA.Check MTSR's competition here
MRNA vs PCVX Comparison June 2026
MRNA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, MRNA stands at 25.4B. In comparison, PCVX has a market cap of 7.4B. Regarding current trading prices, MRNA is priced at $59.75, while PCVX trades at $51.51.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
MRNA currently has a P/E ratio of -7.86, whereas PCVX's P/E ratio is -7.47. In terms of profitability, MRNA's ROE is -0.37%, compared to PCVX's ROE of -0.33%. Regarding short-term risk, MRNA is more volatile compared to PCVX. This indicates potentially higher risk in terms of short-term price fluctuations for MRNA.Check PCVX's competition here
MRNA vs PTGX Comparison June 2026
MRNA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, MRNA stands at 25.4B. In comparison, PTGX has a market cap of 7.3B. Regarding current trading prices, MRNA is priced at $59.75, while PTGX trades at $114.45.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
MRNA currently has a P/E ratio of -7.86, whereas PTGX's P/E ratio is -62.35. In terms of profitability, MRNA's ROE is -0.37%, compared to PTGX's ROE of -0.18%. Regarding short-term risk, MRNA is more volatile compared to PTGX. This indicates potentially higher risk in terms of short-term price fluctuations for MRNA.Check PTGX's competition here
MRNA vs IMVT Comparison June 2026
MRNA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, MRNA stands at 25.4B. In comparison, IMVT has a market cap of 7.3B. Regarding current trading prices, MRNA is priced at $59.75, while IMVT trades at $38.05.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
MRNA currently has a P/E ratio of -7.86, whereas IMVT's P/E ratio is -12.76. In terms of profitability, MRNA's ROE is -0.37%, compared to IMVT's ROE of -0.68%. Regarding short-term risk, MRNA is more volatile compared to IMVT. This indicates potentially higher risk in terms of short-term price fluctuations for MRNA.Check IMVT's competition here
MRNA vs MRUS Comparison June 2026
MRNA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, MRNA stands at 25.4B. In comparison, MRUS has a market cap of 6.8B. Regarding current trading prices, MRNA is priced at $59.75, while MRUS trades at $90.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
MRNA currently has a P/E ratio of -7.86, whereas MRUS's P/E ratio is -17.05. In terms of profitability, MRNA's ROE is -0.37%, compared to MRUS's ROE of -0.51%. Regarding short-term risk, MRNA is more volatile compared to MRUS. This indicates potentially higher risk in terms of short-term price fluctuations for MRNA.Check MRUS's competition here
MRNA vs ACLX Comparison June 2026
MRNA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, MRNA stands at 25.4B. In comparison, ACLX has a market cap of 6.7B. Regarding current trading prices, MRNA is priced at $59.75, while ACLX trades at $115.07.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
MRNA currently has a P/E ratio of -7.86, whereas ACLX's P/E ratio is -28.27. In terms of profitability, MRNA's ROE is -0.37%, compared to ACLX's ROE of -0.55%. Regarding short-term risk, MRNA is more volatile compared to ACLX. This indicates potentially higher risk in terms of short-term price fluctuations for MRNA.Check ACLX's competition here
MRNA vs RYTM Comparison June 2026
MRNA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, MRNA stands at 25.4B. In comparison, RYTM has a market cap of 6.6B. Regarding current trading prices, MRNA is priced at $59.75, while RYTM trades at $98.44.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
MRNA currently has a P/E ratio of -7.86, whereas RYTM's P/E ratio is -30.92. In terms of profitability, MRNA's ROE is -0.37%, compared to RYTM's ROE of -2.03%. Regarding short-term risk, MRNA is more volatile compared to RYTM. This indicates potentially higher risk in terms of short-term price fluctuations for MRNA.Check RYTM's competition here
MRNA vs RETA Comparison June 2026
MRNA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, MRNA stands at 25.4B. In comparison, RETA has a market cap of 6.6B. Regarding current trading prices, MRNA is priced at $59.75, while RETA trades at $172.36.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
MRNA currently has a P/E ratio of -7.86, whereas RETA's P/E ratio is -66.29. In terms of profitability, MRNA's ROE is -0.37%, compared to RETA's ROE of +0.47%. Regarding short-term risk, MRNA is more volatile compared to RETA. This indicates potentially higher risk in terms of short-term price fluctuations for MRNA.Check RETA's competition here
MRNA vs PTCT Comparison June 2026
MRNA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, MRNA stands at 25.4B. In comparison, PTCT has a market cap of 6.6B. Regarding current trading prices, MRNA is priced at $59.75, while PTCT trades at $81.14.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
MRNA currently has a P/E ratio of -7.86, whereas PTCT's P/E ratio is -31.09. In terms of profitability, MRNA's ROE is -0.37%, compared to PTCT's ROE of +1.00%. Regarding short-term risk, MRNA is more volatile compared to PTCT. This indicates potentially higher risk in terms of short-term price fluctuations for MRNA.Check PTCT's competition here
MRNA vs ABVX Comparison June 2026
MRNA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, MRNA stands at 25.4B. In comparison, ABVX has a market cap of 6.5B. Regarding current trading prices, MRNA is priced at $59.75, while ABVX trades at $100.38.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
MRNA currently has a P/E ratio of -7.86, whereas ABVX's P/E ratio is -18.53. In terms of profitability, MRNA's ROE is -0.37%, compared to ABVX's ROE of -1.65%. Regarding short-term risk, MRNA is more volatile compared to ABVX. This indicates potentially higher risk in terms of short-term price fluctuations for MRNA.Check ABVX's competition here
MRNA vs LQDA Comparison June 2026
MRNA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, MRNA stands at 25.4B. In comparison, LQDA has a market cap of 6.3B. Regarding current trading prices, MRNA is priced at $59.75, while LQDA trades at $74.59.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
MRNA currently has a P/E ratio of -7.86, whereas LQDA's P/E ratio is 418.06. In terms of profitability, MRNA's ROE is -0.37%, compared to LQDA's ROE of +0.47%. Regarding short-term risk, MRNA is more volatile compared to LQDA. This indicates potentially higher risk in terms of short-term price fluctuations for MRNA.Check LQDA's competition here
MRNA vs CNTA Comparison June 2026
MRNA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, MRNA stands at 25.4B. In comparison, CNTA has a market cap of 6.2B. Regarding current trading prices, MRNA is priced at $59.75, while CNTA trades at $40.03.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
MRNA currently has a P/E ratio of -7.86, whereas CNTA's P/E ratio is -22.48. In terms of profitability, MRNA's ROE is -0.37%, compared to CNTA's ROE of -0.60%. Regarding short-term risk, MRNA is more volatile compared to CNTA. This indicates potentially higher risk in terms of short-term price fluctuations for MRNA.Check CNTA's competition here
MRNA vs PRAX Comparison June 2026
MRNA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, MRNA stands at 25.4B. In comparison, PRAX has a market cap of 6B. Regarding current trading prices, MRNA is priced at $59.75, while PRAX trades at $298.25.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
MRNA currently has a P/E ratio of -7.86, whereas PRAX's P/E ratio is -21.07. In terms of profitability, MRNA's ROE is -0.37%, compared to PRAX's ROE of -0.43%. Regarding short-term risk, MRNA is more volatile compared to PRAX. This indicates potentially higher risk in terms of short-term price fluctuations for MRNA.Check PRAX's competition here
MRNA vs COGT Comparison June 2026
MRNA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, MRNA stands at 25.4B. In comparison, COGT has a market cap of 5.9B. Regarding current trading prices, MRNA is priced at $59.75, while COGT trades at $35.76.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
MRNA currently has a P/E ratio of -7.86, whereas COGT's P/E ratio is -15.92. In terms of profitability, MRNA's ROE is -0.37%, compared to COGT's ROE of -0.83%. Regarding short-term risk, MRNA is more volatile compared to COGT. This indicates potentially higher risk in terms of short-term price fluctuations for MRNA.Check COGT's competition here
MRNA vs BLTE Comparison June 2026
MRNA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, MRNA stands at 25.4B. In comparison, BLTE has a market cap of 5.9B. Regarding current trading prices, MRNA is priced at $59.75, while BLTE trades at $145.63.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
MRNA currently has a P/E ratio of -7.86, whereas BLTE's P/E ratio is -57.53. In terms of profitability, MRNA's ROE is -0.37%, compared to BLTE's ROE of -0.27%. Regarding short-term risk, MRNA is more volatile compared to BLTE. This indicates potentially higher risk in terms of short-term price fluctuations for MRNA.Check BLTE's competition here
MRNA vs SRRK Comparison June 2026
MRNA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, MRNA stands at 25.4B. In comparison, SRRK has a market cap of 5.7B. Regarding current trading prices, MRNA is priced at $59.75, while SRRK trades at $48.89.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
MRNA currently has a P/E ratio of -7.86, whereas SRRK's P/E ratio is -13.72. In terms of profitability, MRNA's ROE is -0.37%, compared to SRRK's ROE of -1.64%. Regarding short-term risk, MRNA is more volatile compared to SRRK. This indicates potentially higher risk in terms of short-term price fluctuations for MRNA.Check SRRK's competition here
MRNA vs CDTX Comparison June 2026
MRNA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, MRNA stands at 25.4B. In comparison, CDTX has a market cap of 5.6B. Regarding current trading prices, MRNA is priced at $59.75, while CDTX trades at $221.38.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
MRNA currently has a P/E ratio of -7.86, whereas CDTX's P/E ratio is -19.77. In terms of profitability, MRNA's ROE is -0.37%, compared to CDTX's ROE of -0.60%. Regarding short-term risk, MRNA is more volatile compared to CDTX. This indicates potentially higher risk in terms of short-term price fluctuations for MRNA.Check CDTX's competition here
MRNA vs APGE Comparison June 2026
MRNA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, MRNA stands at 25.4B. In comparison, APGE has a market cap of 5.6B. Regarding current trading prices, MRNA is priced at $59.75, while APGE trades at $132.64.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
MRNA currently has a P/E ratio of -7.86, whereas APGE's P/E ratio is -20.87. In terms of profitability, MRNA's ROE is -0.37%, compared to APGE's ROE of -0.33%. Regarding short-term risk, MRNA is more volatile compared to APGE. This indicates potentially higher risk in terms of short-term price fluctuations for MRNA.Check APGE's competition here
MRNA vs ABCM Comparison June 2026
MRNA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, MRNA stands at 25.4B. In comparison, ABCM has a market cap of 5.5B. Regarding current trading prices, MRNA is priced at $59.75, while ABCM trades at $23.99.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
MRNA currently has a P/E ratio of -7.86, whereas ABCM's P/E ratio is 2399.00. In terms of profitability, MRNA's ROE is -0.37%, compared to ABCM's ROE of -0.01%. Regarding short-term risk, MRNA is more volatile compared to ABCM. This indicates potentially higher risk in terms of short-term price fluctuations for MRNA.Check ABCM's competition here
MRNA vs ISEE Comparison June 2026
MRNA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, MRNA stands at 25.4B. In comparison, ISEE has a market cap of 5.5B. Regarding current trading prices, MRNA is priced at $59.75, while ISEE trades at $39.95.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
MRNA currently has a P/E ratio of -7.86, whereas ISEE's P/E ratio is -22.44. In terms of profitability, MRNA's ROE is -0.37%, compared to ISEE's ROE of -0.39%. Regarding short-term risk, MRNA is more volatile compared to ISEE. This indicates potentially higher risk in terms of short-term price fluctuations for MRNA.Check ISEE's competition here
MRNA vs LGND Comparison June 2026
MRNA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, MRNA stands at 25.4B. In comparison, LGND has a market cap of 5.5B. Regarding current trading prices, MRNA is priced at $59.75, while LGND trades at $255.95.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
MRNA currently has a P/E ratio of -7.86, whereas LGND's P/E ratio is 35.84. In terms of profitability, MRNA's ROE is -0.37%, compared to LGND's ROE of +0.16%. Regarding short-term risk, MRNA is more volatile compared to LGND. This indicates potentially higher risk in terms of short-term price fluctuations for MRNA.Check LGND's competition here
MRNA vs CGON Comparison June 2026
MRNA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, MRNA stands at 25.4B. In comparison, CGON has a market cap of 5.4B. Regarding current trading prices, MRNA is priced at $59.75, while CGON trades at $64.90.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
MRNA currently has a P/E ratio of -7.86, whereas CGON's P/E ratio is -26.10. In terms of profitability, MRNA's ROE is -0.37%, compared to CGON's ROE of -0.23%. Regarding short-term risk, MRNA is more volatile compared to CGON. This indicates potentially higher risk in terms of short-term price fluctuations for MRNA.Check CGON's competition here
MRNA vs MIRM Comparison June 2026
MRNA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, MRNA stands at 25.4B. In comparison, MIRM has a market cap of 5.4B. Regarding current trading prices, MRNA is priced at $59.75, while MIRM trades at $108.84.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
MRNA currently has a P/E ratio of -7.86, whereas MIRM's P/E ratio is -7.88. In terms of profitability, MRNA's ROE is -0.37%, compared to MIRM's ROE of -2.89%. Regarding short-term risk, MRNA is more volatile compared to MIRM. This indicates potentially higher risk in terms of short-term price fluctuations for MRNA.Check MIRM's competition here
MRNA vs SYRE Comparison June 2026
MRNA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, MRNA stands at 25.4B. In comparison, SYRE has a market cap of 5.3B. Regarding current trading prices, MRNA is priced at $59.75, while SYRE trades at $99.35.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
MRNA currently has a P/E ratio of -7.86, whereas SYRE's P/E ratio is -41.67. In terms of profitability, MRNA's ROE is -0.37%, compared to SYRE's ROE of -0.31%. Regarding short-term risk, MRNA is more volatile compared to SYRE. This indicates potentially higher risk in terms of short-term price fluctuations for MRNA.Check SYRE's competition here
MRNA vs FBIOX Comparison June 2026
MRNA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, MRNA stands at 25.4B. In comparison, FBIOX has a market cap of 5.3B. Regarding current trading prices, MRNA is priced at $59.75, while FBIOX trades at $26.04.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
MRNA currently has a P/E ratio of -7.86, whereas FBIOX's P/E ratio is N/A. In terms of profitability, MRNA's ROE is -0.37%, compared to FBIOX's ROE of N/A. Regarding short-term risk, MRNA is more volatile compared to FBIOX. This indicates potentially higher risk in terms of short-term price fluctuations for MRNA.Check FBIOX's competition here
MRNA vs APLS Comparison June 2026
MRNA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, MRNA stands at 25.4B. In comparison, APLS has a market cap of 5.3B. Regarding current trading prices, MRNA is priced at $59.75, while APLS trades at $41.03.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
MRNA currently has a P/E ratio of -7.86, whereas APLS's P/E ratio is 38.35. In terms of profitability, MRNA's ROE is -0.37%, compared to APLS's ROE of +0.40%. Regarding short-term risk, MRNA is more volatile compared to APLS. This indicates potentially higher risk in terms of short-term price fluctuations for MRNA.Check APLS's competition here
MRNA vs CAI Comparison June 2026
MRNA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, MRNA stands at 25.4B. In comparison, CAI has a market cap of 5.2B. Regarding current trading prices, MRNA is priced at $59.75, while CAI trades at $17.80.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
MRNA currently has a P/E ratio of -7.86, whereas CAI's P/E ratio is -6.69. In terms of profitability, MRNA's ROE is -0.37%, compared to CAI's ROE of +0.06%. Regarding short-term risk, MRNA is more volatile compared to CAI. This indicates potentially higher risk in terms of short-term price fluctuations for MRNA.Check CAI's competition here
MRNA vs CRSP Comparison June 2026
MRNA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, MRNA stands at 25.4B. In comparison, CRSP has a market cap of 5.2B. Regarding current trading prices, MRNA is priced at $59.75, while CRSP trades at $54.27.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
MRNA currently has a P/E ratio of -7.86, whereas CRSP's P/E ratio is -8.77. In terms of profitability, MRNA's ROE is -0.37%, compared to CRSP's ROE of -0.31%. Regarding short-term risk, MRNA is more volatile compared to CRSP. This indicates potentially higher risk in terms of short-term price fluctuations for MRNA.Check CRSP's competition here
MRNA vs LEGN Comparison June 2026
MRNA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, MRNA stands at 25.4B. In comparison, LEGN has a market cap of 5.2B. Regarding current trading prices, MRNA is priced at $59.75, while LEGN trades at $29.02.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
MRNA currently has a P/E ratio of -7.86, whereas LEGN's P/E ratio is -20.24. In terms of profitability, MRNA's ROE is -0.37%, compared to LEGN's ROE of -0.25%. Regarding short-term risk, MRNA is more volatile compared to LEGN. This indicates potentially higher risk in terms of short-term price fluctuations for MRNA.Check LEGN's competition here
MRNA vs TVTX Comparison June 2026
MRNA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, MRNA stands at 25.4B. In comparison, TVTX has a market cap of 5.1B. Regarding current trading prices, MRNA is priced at $59.75, while TVTX trades at $55.63.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
MRNA currently has a P/E ratio of -7.86, whereas TVTX's P/E ratio is -110.30. In terms of profitability, MRNA's ROE is -0.37%, compared to TVTX's ROE of -0.27%. Regarding short-term risk, MRNA is more volatile compared to TVTX. This indicates potentially higher risk in terms of short-term price fluctuations for MRNA.Check TVTX's competition here
MRNA vs TERN Comparison June 2026
MRNA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, MRNA stands at 25.4B. In comparison, TERN has a market cap of 4.8B. Regarding current trading prices, MRNA is priced at $59.75, while TERN trades at $52.95.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
MRNA currently has a P/E ratio of -7.86, whereas TERN's P/E ratio is -51.41. In terms of profitability, MRNA's ROE is -0.37%, compared to TERN's ROE of -0.20%. Regarding short-term risk, MRNA is more volatile compared to TERN. This indicates potentially higher risk in terms of short-term price fluctuations for MRNA.Check TERN's competition here
MRNA vs FOLD Comparison June 2026
MRNA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, MRNA stands at 25.4B. In comparison, FOLD has a market cap of 4.5B. Regarding current trading prices, MRNA is priced at $59.75, while FOLD trades at $14.49.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
MRNA currently has a P/E ratio of -7.86, whereas FOLD's P/E ratio is -161.00. In terms of profitability, MRNA's ROE is -0.37%, compared to FOLD's ROE of -0.12%. Regarding short-term risk, MRNA is more volatile compared to FOLD. This indicates potentially higher risk in terms of short-term price fluctuations for MRNA.Check FOLD's competition here
MRNA vs AKRO Comparison June 2026
MRNA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, MRNA stands at 25.4B. In comparison, AKRO has a market cap of 4.5B. Regarding current trading prices, MRNA is priced at $59.75, while AKRO trades at $54.65.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
MRNA currently has a P/E ratio of -7.86, whereas AKRO's P/E ratio is -14.57. In terms of profitability, MRNA's ROE is -0.37%, compared to AKRO's ROE of -0.31%. Regarding short-term risk, MRNA is more volatile compared to AKRO. This indicates potentially higher risk in terms of short-term price fluctuations for MRNA.Check AKRO's competition here
MRNA vs ALPN Comparison June 2026
MRNA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, MRNA stands at 25.4B. In comparison, ALPN has a market cap of 4.5B. Regarding current trading prices, MRNA is priced at $59.75, while ALPN trades at $64.97.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
MRNA currently has a P/E ratio of -7.86, whereas ALPN's P/E ratio is -101.52. In terms of profitability, MRNA's ROE is -0.37%, compared to ALPN's ROE of -0.13%. Regarding short-term risk, MRNA is more volatile compared to ALPN. This indicates potentially higher risk in terms of short-term price fluctuations for MRNA.Check ALPN's competition here
MRNA vs CELC Comparison June 2026
MRNA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, MRNA stands at 25.4B. In comparison, CELC has a market cap of 4.3B. Regarding current trading prices, MRNA is priced at $59.75, while CELC trades at $89.91.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
MRNA currently has a P/E ratio of -7.86, whereas CELC's P/E ratio is -22.50. In terms of profitability, MRNA's ROE is -0.37%, compared to CELC's ROE of -2.45%. Regarding short-term risk, MRNA is more volatile compared to CELC. This indicates potentially higher risk in terms of short-term price fluctuations for MRNA.Check CELC's competition here
MRNA vs VCYT Comparison June 2026
MRNA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, MRNA stands at 25.4B. In comparison, VCYT has a market cap of 4.3B. Regarding current trading prices, MRNA is priced at $59.75, while VCYT trades at $53.62.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
MRNA currently has a P/E ratio of -7.86, whereas VCYT's P/E ratio is 49.66. In terms of profitability, MRNA's ROE is -0.37%, compared to VCYT's ROE of +0.07%. Regarding short-term risk, MRNA is more volatile compared to VCYT. This indicates potentially higher risk in terms of short-term price fluctuations for MRNA.Check VCYT's competition here
MRNA vs ERAS Comparison June 2026
MRNA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, MRNA stands at 25.4B. In comparison, ERAS has a market cap of 4.3B. Regarding current trading prices, MRNA is priced at $59.75, while ERAS trades at $15.06.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
MRNA currently has a P/E ratio of -7.86, whereas ERAS's P/E ratio is -14.70. In terms of profitability, MRNA's ROE is -0.37%, compared to ERAS's ROE of -0.77%. Regarding short-term risk, MRNA is more volatile compared to ERAS. This indicates potentially higher risk in terms of short-term price fluctuations for MRNA.Check ERAS's competition here
MRNA vs OPT Comparison June 2026
MRNA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, MRNA stands at 25.4B. In comparison, OPT has a market cap of 4.2B. Regarding current trading prices, MRNA is priced at $59.75, while OPT trades at $3.41.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
MRNA currently has a P/E ratio of -7.86, whereas OPT's P/E ratio is -1.52. In terms of profitability, MRNA's ROE is -0.37%, compared to OPT's ROE of +1.09%. Regarding short-term risk, MRNA is more volatile compared to OPT. This indicates potentially higher risk in terms of short-term price fluctuations for MRNA.Check OPT's competition here
MRNA vs XENE Comparison June 2026
MRNA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, MRNA stands at 25.4B. In comparison, XENE has a market cap of 4.2B. Regarding current trading prices, MRNA is priced at $59.75, while XENE trades at $54.73.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
MRNA currently has a P/E ratio of -7.86, whereas XENE's P/E ratio is -11.26. In terms of profitability, MRNA's ROE is -0.37%, compared to XENE's ROE of -0.49%. Regarding short-term risk, MRNA is more volatile compared to XENE. This indicates potentially higher risk in terms of short-term price fluctuations for MRNA.Check XENE's competition here
MRNA vs KNSA Comparison June 2026
MRNA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, MRNA stands at 25.4B. In comparison, KNSA has a market cap of 4.1B. Regarding current trading prices, MRNA is priced at $59.75, while KNSA trades at $57.57.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
MRNA currently has a P/E ratio of -7.86, whereas KNSA's P/E ratio is 60.56. In terms of profitability, MRNA's ROE is -0.37%, compared to KNSA's ROE of +0.13%. Regarding short-term risk, MRNA is more volatile compared to KNSA. This indicates potentially higher risk in terms of short-term price fluctuations for MRNA.Check KNSA's competition here
MRNA vs MRTX Comparison June 2026
MRNA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, MRNA stands at 25.4B. In comparison, MRTX has a market cap of 4.1B. Regarding current trading prices, MRNA is priced at $59.75, while MRTX trades at $58.70.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
MRNA currently has a P/E ratio of -7.86, whereas MRTX's P/E ratio is -4.82. In terms of profitability, MRNA's ROE is -0.37%, compared to MRTX's ROE of -0.62%. Regarding short-term risk, MRNA is more volatile compared to MRTX. This indicates potentially higher risk in terms of short-term price fluctuations for MRNA.Check MRTX's competition here
MRNA vs EWTX Comparison June 2026
MRNA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, MRNA stands at 25.4B. In comparison, EWTX has a market cap of 4B. Regarding current trading prices, MRNA is priced at $59.75, while EWTX trades at $36.81.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
MRNA currently has a P/E ratio of -7.86, whereas EWTX's P/E ratio is -22.17. In terms of profitability, MRNA's ROE is -0.37%, compared to EWTX's ROE of -0.33%. Regarding short-term risk, MRNA is more volatile compared to EWTX. This indicates potentially higher risk in terms of short-term price fluctuations for MRNA.Check EWTX's competition here
MRNA vs MANE Comparison June 2026
MRNA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, MRNA stands at 25.4B. In comparison, MANE has a market cap of 3.9B. Regarding current trading prices, MRNA is priced at $59.75, while MANE trades at $105.69.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
MRNA currently has a P/E ratio of -7.86, whereas MANE's P/E ratio is -35.42. In terms of profitability, MRNA's ROE is -0.37%, compared to MANE's ROE of -0.95%. Regarding short-term risk, MRNA is more volatile compared to MANE. This indicates potentially higher risk in terms of short-term price fluctuations for MRNA.Check MANE's competition here
MRNA vs CPRX Comparison June 2026
MRNA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, MRNA stands at 25.4B. In comparison, CPRX has a market cap of 3.8B. Regarding current trading prices, MRNA is priced at $59.75, while CPRX trades at $31.38.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
MRNA currently has a P/E ratio of -7.86, whereas CPRX's P/E ratio is 18.14. In terms of profitability, MRNA's ROE is -0.37%, compared to CPRX's ROE of +0.24%. Regarding short-term risk, MRNA is more volatile compared to CPRX. This indicates potentially higher risk in terms of short-term price fluctuations for MRNA.Check CPRX's competition here
MRNA vs CRNX Comparison June 2026
MRNA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, MRNA stands at 25.4B. In comparison, CRNX has a market cap of 3.8B. Regarding current trading prices, MRNA is priced at $59.75, while CRNX trades at $35.44.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
MRNA currently has a P/E ratio of -7.86, whereas CRNX's P/E ratio is -6.98. In terms of profitability, MRNA's ROE is -0.37%, compared to CRNX's ROE of -0.44%. Regarding short-term risk, MRNA is more volatile compared to CRNX. This indicates potentially higher risk in terms of short-term price fluctuations for MRNA.Check CRNX's competition here
MRNA vs RYZB Comparison June 2026
MRNA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, MRNA stands at 25.4B. In comparison, RYZB has a market cap of 3.8B. Regarding current trading prices, MRNA is priced at $59.75, while RYZB trades at $62.49.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
MRNA currently has a P/E ratio of -7.86, whereas RYZB's P/E ratio is -57.86. In terms of profitability, MRNA's ROE is -0.37%, compared to RYZB's ROE of +0.83%. Regarding short-term risk, MRNA is more volatile compared to RYZB. This indicates potentially higher risk in terms of short-term price fluctuations for MRNA.Check RYZB's competition here
MRNA vs CBAY Comparison June 2026
MRNA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, MRNA stands at 25.4B. In comparison, CBAY has a market cap of 3.7B. Regarding current trading prices, MRNA is priced at $59.75, while CBAY trades at $32.48.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
MRNA currently has a P/E ratio of -7.86, whereas CBAY's P/E ratio is -32.81. In terms of profitability, MRNA's ROE is -0.37%, compared to CBAY's ROE of -0.64%. Regarding short-term risk, MRNA is more volatile compared to CBAY. This indicates potentially higher risk in terms of short-term price fluctuations for MRNA.Check CBAY's competition here
MRNA vs ACAD Comparison June 2026
MRNA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, MRNA stands at 25.4B. In comparison, ACAD has a market cap of 3.7B. Regarding current trading prices, MRNA is priced at $59.75, while ACAD trades at $22.24.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
MRNA currently has a P/E ratio of -7.86, whereas ACAD's P/E ratio is 9.78. In terms of profitability, MRNA's ROE is -0.37%, compared to ACAD's ROE of +0.36%. Regarding short-term risk, MRNA is more volatile compared to ACAD. This indicates potentially higher risk in terms of short-term price fluctuations for MRNA.Check ACAD's competition here
MRNA vs DNLI Comparison June 2026
MRNA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, MRNA stands at 25.4B. In comparison, DNLI has a market cap of 3.7B. Regarding current trading prices, MRNA is priced at $59.75, while DNLI trades at $23.97.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
MRNA currently has a P/E ratio of -7.86, whereas DNLI's P/E ratio is -8.09. In terms of profitability, MRNA's ROE is -0.37%, compared to DNLI's ROE of -0.52%. Regarding short-term risk, MRNA is more volatile compared to DNLI. This indicates potentially higher risk in terms of short-term price fluctuations for MRNA.Check DNLI's competition here
MRNA vs SWTX Comparison June 2026
MRNA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, MRNA stands at 25.4B. In comparison, SWTX has a market cap of 3.5B. Regarding current trading prices, MRNA is priced at $59.75, while SWTX trades at $46.99.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
MRNA currently has a P/E ratio of -7.86, whereas SWTX's P/E ratio is -13.78. In terms of profitability, MRNA's ROE is -0.37%, compared to SWTX's ROE of -0.36%. Regarding short-term risk, MRNA is more volatile compared to SWTX. This indicates potentially higher risk in terms of short-term price fluctuations for MRNA.Check SWTX's competition here
MRNA vs VKTX Comparison June 2026
MRNA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, MRNA stands at 25.4B. In comparison, VKTX has a market cap of 3.5B. Regarding current trading prices, MRNA is priced at $59.75, while VKTX trades at $32.21.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
MRNA currently has a P/E ratio of -7.86, whereas VKTX's P/E ratio is -7.32. In terms of profitability, MRNA's ROE is -0.37%, compared to VKTX's ROE of -0.71%. Regarding short-term risk, MRNA is more volatile compared to VKTX. This indicates potentially higher risk in terms of short-term price fluctuations for MRNA.Check VKTX's competition here
MRNA vs NAMSW Comparison June 2026
MRNA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, MRNA stands at 25.4B. In comparison, NAMSW has a market cap of 3.5B. Regarding current trading prices, MRNA is priced at $59.75, while NAMSW trades at $18.70.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
MRNA currently has a P/E ratio of -7.86, whereas NAMSW's P/E ratio is N/A. In terms of profitability, MRNA's ROE is -0.37%, compared to NAMSW's ROE of -0.30%. Regarding short-term risk, MRNA is more volatile compared to NAMSW. This indicates potentially higher risk in terms of short-term price fluctuations for MRNA.Check NAMSW's competition here
MRNA vs BEAM Comparison June 2026
MRNA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, MRNA stands at 25.4B. In comparison, BEAM has a market cap of 3.5B. Regarding current trading prices, MRNA is priced at $59.75, while BEAM trades at $35.36.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
MRNA currently has a P/E ratio of -7.86, whereas BEAM's P/E ratio is -69.67. In terms of profitability, MRNA's ROE is -0.37%, compared to BEAM's ROE of -0.06%. Regarding short-term risk, MRNA is more volatile compared to BEAM. This indicates potentially higher risk in terms of short-term price fluctuations for MRNA.Check BEAM's competition here
MRNA vs NAMS Comparison June 2026
MRNA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, MRNA stands at 25.4B. In comparison, NAMS has a market cap of 3.5B. Regarding current trading prices, MRNA is priced at $59.75, while NAMS trades at $29.96.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
MRNA currently has a P/E ratio of -7.86, whereas NAMS's P/E ratio is -16.76. In terms of profitability, MRNA's ROE is -0.37%, compared to NAMS's ROE of -0.30%. Regarding short-term risk, MRNA is more volatile compared to NAMS. This indicates potentially higher risk in terms of short-term price fluctuations for MRNA.Check NAMS's competition here
MRNA vs TNGX Comparison June 2026
MRNA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, MRNA stands at 25.4B. In comparison, TNGX has a market cap of 3.5B. Regarding current trading prices, MRNA is priced at $59.75, while TNGX trades at $28.31.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
MRNA currently has a P/E ratio of -7.86, whereas TNGX's P/E ratio is -33.70. In terms of profitability, MRNA's ROE is -0.37%, compared to TNGX's ROE of -0.42%. Regarding short-term risk, MRNA is more volatile compared to TNGX. This indicates potentially higher risk in terms of short-term price fluctuations for MRNA.Check TNGX's competition here